5 completed, 3 active not recruiting, 2 recruiting, 2 withdrawn. 10 Phase 2, 7 Phase 1, 1 Phase 3.
Follow this condition Literature Review of Recurrent Burkitt Lymphoma trials Research Report on Recurrent Burkitt Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Clofarabine - Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2021-10-29 | 2024-01-12 | |
| Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Bortezomib, Rituximab, Venetoclax - High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Burkitt Lymphoma | Phase 2 | Withdrawn | Rutgers, The State University of New Jersey | 2020-05-06 | 2026-01-30 | |
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Nivolumab, Varlilumab - ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2018-12-21 | 2026-05-12 |
| Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia Bortezomib, Clofarabine, Cyclophosphamide - Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 42 | 2017-08-09 | 2026-08-10 |
| Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Lenalidomide, Obinutuzumab, Venetoclax - B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma | Phase 1 | Active not recruiting | Beth Christian | 22 | 2017-02-21 | 2026-09-24 |
| Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Nivolumab - Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma | Phase 1 / Phase 2 | Completed | David Bond, MD | 36 | 2017-02-14 | 2026-09-23 |
| Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pembrolizumab - B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Grade 1 Follicular Lymphoma | Phase 1 | Completed | Kami Maddocks | 2 | 2017-01-12 | 2019-07-30 |
| Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma Blinatumomab, Lenalidomide - Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 35 | 2016-11-15 | 2025-11-26 |
| Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | AIDS Malignancy Consortium | 11 | 2016-06-23 | 2026-05-18 |
| Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide - AIDS-Related Burkitt Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 14 | 2015-01-14 | 2024-06-11 |
| Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas Alisertib, Laboratory Biomarker Analysis, Romidepsin - MYC Positive, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 26 | 2013-07-17 | 2019-01-28 |
| High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate - Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Diffuse Large Cell Lymphoma | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 20 | 2011-11-16 | 2021-07-20 |
| Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia Blinatumomab, Cyclophosphamide, Cytarabine - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 276 | 2011-08-26 | 2026-07-15 |
Burkitt Lymphoma (14) · Lymphoma, Large B-Cell, Diffuse (9) · Lymphoma, B-Cell (6) · Lymphoma, Follicular (6) · Lymphoma, Mantle-Cell (5) · Lymphoma, B-Cell, Marginal Zone (4) · Lymphoma, T-Cell (3) · Hodgkin Disease (2) · Lymphoma, Non-Hodgkin (2) · Plasmablastic Lymphoma (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Waldenstrom Macroglobulinemia (2) · HIV Infections (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphoma, Primary Effusion (1)
DNA Virus Infections (14) · Epstein-Barr Virus Infections (14) · Hemic and Lymphatic Diseases (14) · Herpesviridae Infections (14) · Immune System Diseases (14) · Immunoproliferative Disorders (14) · Infections (14) · Lymphatic Diseases (14) · Lymphoma (14) · Lymphoproliferative Disorders (14) · Neoplasms (14) · Neoplasms by Histologic Type (14) · Tumor Virus Infections (14) · Virus Diseases (14) · Lymphoma, Non-Hodgkin (12)
Rituximab (7) · CT-P10 (6) · Cyclophosphamide (5) · Etoposide (4) · Vincristine (4) · Cytarabine (3) · Lenalidomide (3) · Prednisone (3) · Bortezomib (2) · Clofarabine (2) · Dexamethasone (2) · Doxorubicin (2) · Methotrexate (2) · Mycophenolic Acid (2) · Nivolumab (2)
M.D. Anderson Cancer Center (4) · National Cancer Institute (NCI) (4) · AIDS Malignancy Consortium (1) · Beth Christian (1) · David Bond, MD (1) · Fred Hutchinson Cancer Center (1) · Kami Maddocks (1) · Rutgers, The State University of New Jersey (1)
United States (12)
Elias Jabbour, MD (2) · Ajay Gopal (1) · Beth Christian, MD (1) · David Bond, MD (1) · Hun Lee (1) · Joseph M Tuscano (1) · Kami Maddocks, MD (1) · Kristie A Blum (1) · Maro Ohanian (1) · Mehrdad Abedi (1) · Rajat Bannerji (1) · Stephen M Ansell (1) · Yago L Nieto (1)
PMID 28859185, PMID 29352703, PMID 35622074, PMID 37131217, PMID 37187201, PMID 38551807, PMID 41671463
P01CA044991 (1), P30CA015704 (1), P30CA016058 (1), P30CA016672 (1), P30CA072720 (1), U01CA062461 (1), U01CA121947 (1), U10CA180821 (1), UM1CA186644 (1), UM1CA186686 (1), UM1CA186688 (1), UM1CA186709 (1), UM1CA186717 (1)